image credit: Pexels

BridgeBio shares jump on dwarfism drug data

Based on the latest data, BridgeBio has started enrolling children in a Phase 3 trial of infigratinib in achondroplasia and also plans to develop the medicine for patients with a closely related skeletal abnormality known as hypochondroplasia.

The company has a high bar to meet. Though achondroplasia can cause health complications beyond short stature, it’s not life-threatening. The Cleveland Clinic advises parents of children diagnosed with the condition that it “won’t hinder your child’s ability to live a happy and healthy life.”

Read More on Biopharma Dive